Taro Pharmaceutical Industries Ltd (TARO) Return on Investment ROI from the fourth quarter of 2023 to fourth quarter of 2022 and for the year 2023, average high and low, overall ranking from Mar 31 2023 to Mar 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Taro Pharmaceutical Industries Ltd  (NYSE: TARO)


Taro Pharmaceutical Industries Ltd's ROI from its fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Taro Pharmaceutical Industries Ltd's ROI in the fourth quarter of 2023?
Taro Pharmaceutical Industries Ltd achieved a return on average invested assets (ROI) of 1.45 % in its fourth quarter of 2023, which is below Taro Pharmaceutical Industries Ltd's average return on investment, which stands at 16%.

ROI fell compared to the third quarter of 2023, despite the net income growth of % from the third quarter of 2023.

Within the Healthcare sector 189 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2023 from to 2344.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2023)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Mar 31 2022)
IV. Quarter
Y / Y Investment Change TTM 1.64 % 1.36 % -4.59 % -9.92 % -14.97 %
Y / Y Net Income Change TTM -56.33 % - - - -
Investment (TTM) in Millions 1,750 1,750 1,750 1,770 1,745
Return On Investment (TTM) 1.45 % 3.32 % 3.34 % 3.35 % 3.37 %
TARO's Overall Ranking # 2344 # # # # 2343
Seq. Investment Change TTM 0.07 % 0.42 % 0.42 % 0.72 % -0.21 %
Seq. Net Income Change TTM -56.33 % 0 % 0 % 0 % -
Net Income (TTM) in Millions 25 58 58 58 58

TARO Company Profile >> Back to TARO Roi Comparisons >> See Annual TARO Return On Investment



Return On Investment TARO's Ranking
Within: No.
Industry # 69
Sector # 190
Overall # 2344

Return On Investment Statistics
High Average Low
40.08 %
16 %
-22.75 %
(Mar 31 2013)   (Mar 31 2021)







Financial Statements
Taro Pharmaceutical Industries Ltd's IV. Quarter Investments $ 1,750 Millions TARO's Balance sheet
Taro Pharmaceutical Industries Ltd's IV. Quarter Income $ 25 Millions Quarterly TARO's Income Statement
TARO's Income by Division See TARO's Income by Division


TARO Annual Return On Investment (Mar 31 2023)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2021		 (Mar 31 2020)
2020		 (Mar 31 2019)
2019
Total Investments in Millions 1,770 1,778 1,759 2,132 1,934
Y / Y Investment Growth -0.43 % 1.04 % -17.49 % 10.28 % -13.08 %
Net Income in Millions 25 58 -401 245 282
Y / Y Net Income Growth -56.33 % - - -13.32 % 34.29 %
Annual Return On Investment 1.44 % 3.28 % -22.78 % 11.47 % 14.59 %


Annual Roi Comment
In the fiscal year 2023 ROI decreased relative to the previous year to 1.44 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TARO's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TARO's Competitors
Subscribers only: Roi for Taro Pharmaceutical Industries Ltd's Suppliers
Subscribers only: Return On Investment for TARO's Customers

Other Ratios
TARO's Roa TARO's Inventory Turnover Ratio TARO's Growth Rates TARO's Dividend Statistics
TARO's Profitability Ratios TARO's Asset Turnover Ratio TARO's Dividend Growth
TARO's Roe TARO's Valuation Ratios TARO's Financial Strength Ratios TARO's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2023, within Healthcare Sector ROI
Phibro Animal Health Corporation  3.90 %
Pacific Health Care Organization Inc  3.84 %
Tenet Healthcare Corp  3.83 %
Organogenesis Holdings Inc   3.81 %
Becton Dickinson And Company  3.77 %
Precision Optics Corporation Inc   3.76 %
Celularity Inc   3.61 %
Neurocrine Biosciences Inc   3.56 %
Select Medical Holdings Corp  3.45 %
Boston Scientific Corporation  3.33 %
Puma Biotechnology Inc   3.10 %
Ligand Pharmaceuticals Incorporated  2.98 %
Vanda Pharmaceuticals Inc   2.98 %
Royalty Pharma Plc  2.98 %
Takeda Pharmaceutical Company Limited  2.97 %
American Shared Hospital Services  2.92 %
American Oncology Network Inc   2.82 %
Hh and l Acquisition Co   2.79 %
Avanos Medical Inc   2.78 %
The Cooper Companies Inc   2.76 %
Nature s Sunshine Products inc   2.67 %
Northview Acquisition Corp  2.65 %
Skinhealth Systems Inc   2.60 %
Integer Holdings Corporation  2.48 %
Zimmer Biomet Holdings Inc   2.37 %
Privia Health Group Inc   2.28 %
Apeiron Capital Investment Corp   2.27 %
Syneos Health Inc   2.26 %
Schrodinger Inc   2.24 %
10x Capital Venture Acquisition Corp Iii  2.20 %

Date modified: 2023-06-30T08:25:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.